DexCom Inc. (DXCM) Revenue-to-Profit Sankey Flow & SEC XBRL Financials
$79.93 +1.67% NASDAQ • Public Delayed / 60s Snapshot
DexCom Inc. (DXCM) earns a Roarable Rating of B (Buy) with 73/100 RQD Confidence. High-quality cash engine (60% profit margin, 22% return on capital) with steady institutional support. Even if the broader market gets choppy, the company’s underlying cash engine and big-money support put the odds in buyers’ favor.
ROARABLE B • BUY
Cap $30.16B
INTERACTIVE SCENARIO DECK:
RQD QUANT TACHOMETERBUY • B
2-of-3 JEV AI Jury Bullish
Cash
SEC
Whale
5-PILLAR SNOWFLAKE RADARRw C+ · Rk B+
Each axis scored 0–20
12M PRICE TARGET CONE+6.8% Base Target
WHALE OPTIONS TUG-OF-WAR:54% Call Buyers ($2.9M)
46% PutsMax Pain: $78.00
VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)
How DXCM Turns Every Dollar of Sales Into Real Bottom-Line Profit
Free Cash Flow:$1.08B (23.1% FCF Margin)
Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory
■ Revenue■ Net Profit■ Free Cash Flow
FY23
Rev $3.62B
FY24
Rev $4.03B
FY25
Rev $4.66B
| Fiscal Year | Revenue | Gross Margin | Op Margin | Net Profit | Free Cash Flow | ROIC % |
|---|---|---|---|---|---|---|
| FY 2025 | $4.66B | 60.1% | 19.6% | $836.3M | $1.08B | 20.9% |
| FY 2024 | $4.03B | 60.5% | 14.9% | $576.2M | $630.7M | 13.7% |
| FY 2023 | $3.62B | 44% | 16.5% | $541.5M | $585.5M | 4.7% |
🔴 SUNDAY NIGHT PREP • 7:00 PM ETHosted Live by Perry Belcher & Guest Forensic Quant Desk
Red-Light Warning Desk: How Pros Profit When Overhyped Stocks Crack (Featuring DXCM)
- ✓Live walkthrough of DXCM's RQD Radar, SEC cash-conversion gap & downside levels
- ✓3 asymmetric Bear/Hedge setups institutions use when 10-year yields stay elevated
- ✓Includes instant 24/7 email alert whenever any of your stocks flip to Red
RQD INSIDER CLUB UPGRADE$49/YEAR
Want Plain-English AI Custom Indicators, Daily Pro Trader Video Clips & SMS Crash Alerts?
DXCM // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +38.19%📐 WEDGE COMPRESSION COIL
2026-10-30O $81.52H $85.25L $79.79C $82.29VOL 8.64M
RES: $87.89SUP: $76.97SMA50: $85.82SMA200: $74.56
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
DXCM Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
27.8%/yr Implied 5Y Growth
vs. +15.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on DXCM today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
LLY → DXCM Analyst Hypothesis
Real-world payer claims data show clinicians co-prescribe Dexcom G7 and OTC Stelo continuous glucose monitors (CGMs) alongside GLP-1 initiation for metabolic feedback, offsetting delayed progression to basal insulin.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for DXCM today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DXCM Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDHow profitable is DexCom Inc. (DXCM)?
In FY 2025 (10-K), DXCM converted $4.7B of revenue into a 60.1% gross margin, 19.6% operating margin, and $1.1B in free cash flow (23.1% FCF margin).